A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

NCT07266324 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Prader-Willi Syndrome

Interventions

DRUG: BMB-101
DRUG: Placebo

Sponsor

Bright Minds Biosciences Pty Ltd